Overview
Ascelia Pharma is a biotech company specializing in the development and commercialization of novel drugs for orphan oncology indications, addressing unmet medical needs in rare cancers. Their lead candidate, Orviglance, is a Phase 3 liver-specific MRI contrast agent for detecting metastases in patients unable to use gadolinium-based agents. Oncoral, an oral irinotecan formulation, has completed Phase 1 trials for advanced gastric cancer and is advancing to Phase 2, with active pursuit of partnerships for clinical development and global commercialization.
Frequently asked questions
- What are Ascelia Pharma's key drug candidates and development stages?
- Orviglance is in Phase 3 for liver MRI contrast in oncology patients contraindicated for gadolinium agents. Oncoral, an oral irinotecan for gastric cancer, completed Phase 1 and plans Phase 2 studies.
- What partnering opportunities does Ascelia offer?
- Ascelia seeks commercialization partners for Orviglance in the US and regions, and clinical development partners for Oncoral. They pursue collaborations in orphan oncology from universities to biotech firms.
- Where is Ascelia Pharma based and what is their therapeutic focus?
- Headquartered in Malmö, Sweden, Ascelia focuses on orphan oncology drugs for rare cancers, developing treatments with clear regulatory pathways.